Skip to main content
Leonard Farber, MD, Radiation Oncology, Westbury, NY

LeonardAFarberMD

Radiation Oncology Westbury, NY

Breast Cancer, Gastrointestinal Cancer, Head & Neck, Skin Cancer

Chief Clinical and Medical Affairs Officer

Dr. Farber is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Farber's full profile

Already have an account?

  • Office

    695 Merrick Ave
    #539
    Westbury, NY 11590
    Phone+1 917-514-9333

Summary

  • I am a Board Certified physician in Radiation Oncology. I have been in private practice for over a decade, recently opened and founded The Farber Center for Radiation Oncology in Tribeca NYC. Before I opened The Farber Center, I served as Chairman of Radiation Oncology at Staten Island University Hospital. I specialize in adult radiation oncology, with particular focus on breast cancer, prostate cancer and gastrointestinal malignancies, lymphomas, head and neck cancers and lung cancers. I am an expert in HDR brachytherapy for various types of cancers, including breast, skin and gynecologic malignancies, and intracranial and body radiosurgery.

    After receiving my B.S. and B.A. at the State University of New York at Binghamton, I pursued my M.D. at the Mt. Sinai School of Medicine in New York. Following an internship in internal medicine at Beth Israel Medical Center in New York, I did my residency in Radiation Oncology at the Hospital of the University of Pennsylvania in Philadelphia, where I served as Chief Resident. I am a member of the American Society for Therapeutic Radiology and Oncology, the American College of Radiation Oncology, the American Radium Society, the American Brachytherapy Society, the New York Cancer Society, the New York Metropolitan Breast Cancer Group, the New York Head & Neck Society, and the Long Island Oncology Network.

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemChief Residency, Radiation Oncology, 1997 - 1998
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Radiation Oncology, 1995 - 1997
  • Icahn School of Medicine at Mount Sinai/Beth Israel
    Icahn School of Medicine at Mount Sinai/Beth IsraelInternship, Internal Medicine, 1994 - 1995
  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiClass of 1994, MD
  • State University of New York
    State University of New YorkBS/BA, 1990

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2017 - 2025
  • NY State Medical License
    NY State Medical License 1998 - 2025
  • LA State Medical License
    LA State Medical License 2021 - 2023
  • MI State Medical License
    MI State Medical License 2020 - 2023
  • NJ State Medical License
    NJ State Medical License 2010 - 2019
  • PA State Medical License
    PA State Medical License 1996 - 2016
  • CT State Medical License
    CT State Medical License 2009 - 2013
  • American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

  • Best Doctors Best Doctors, 2012
  • Super Doctors Super Doctors, 2012
  • America’s Top Oncologists Award in Radiation Oncology Consumers Research Council of America (2005) (2009) (2010), 2011
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Comparison of Conventional Versus Conformal External Bean Irradiation of a Stented Coronary Artery Utilizing a New Fluoroscopic Imaging Detector System.  
    Farber LA, Bloch P, York ED, Stevens CW, Herrmann H, Ruffer J, Cardiovascular Radiation Medicine 1(1): 1999;80-85
  • Detection of Recurrent Head and Neck Squamous Cell Carcinomas after Radiation Therapy with 218-F-Fluoro-2deoxy-D-glucose Positron Emission Tomography.  
    Farber LA, Bernard F, Machtay M, Alavi A, Smith RJ, Weber RS, Weinstein GS, Rosenthal DI, Laryngoscope 109: 1999;970-975
  • Dual Time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the ...  
    Hustinx R, Smith RJ, Bernard F, Rosenthal DI, Machtay M, Farber LA, Alavi A, European Journal of Nuclear Medicine, 26: 1999;1345-1348
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Dynamic Contrast Enhanced MRI Of The Prostate Utilizing New Computer Software – An Initial Experience.
    Berkovich GY, Waldbaum R, Steckel J, Farber LA, Badillo F, Nochomowitz L, American Urological Association New York Section 104th Annual Meeting, New Delhi, India
  • Feasibility of Conformal External Beam Irradiation of Stented Coronary Artery.
    Bloch P, Farber LA, York ED, Ruffer JE, Herrmann H, Proceedings of the Scripps Clinic & Research Foundation- Second Annual Symposium on Radiotherapy...
  • The Use of Conformal External Beam Irradiation to Prevent or Reduce Restenosis in a Stented Coronary Artery Following Percutaneous Coronary Angioplasty.
    Farber LA, Bloch P, York ED, Stevens CW, Herrmann H, Ruffer JE, Advances in Cardiovascular Radiation Therapy Syllabus
  • Join now to see all

Lectures

  • Rhabdomyosarcoma of the Nasopharynx. 
    Childrens Hospital of Pennsylvania Cancer Center
  • History of Radiotherapy and Review of Intravascular Radiotherapy. 
    6th Annual International Interventional Cardiology Fellows Course, San Jose, CA
  • The Management of Pediatrics Medulloblastomas. 
    Hospital of the University of Pennsylvania Cancer Center
  • Join now to see all

Other

  • Utilization of a diagnostic related group (DRG) computer system to analyze the frequency of thromboembolic complications in solid tumor malignancies. 
    Farber LA, DiGiovanni G, Bruckner HW, OncoLink
    http://www.oncolink.upenn.edu

Press Mentions

  • NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
    NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic CancerNovember 14th, 2022
  • NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 plus Anti-PD-1 for Patients with Advanced Cancers
    NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 plus Anti-PD-1 for Patients with Advanced CancersJuly 20th, 2023

Other Languages

  • Spanish, Chinese (Mandarin), Russian, Chinese (Cantonese)